Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age

A Phase II, Observer-blind, Randomized Study to Evaluate the Immunogenicity, Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Combined DssiTgdPa-HBV-IPV/Hib Vaccine Containing Diphtheria Toxoid From the Statens Serum Institute (SSI) of Denmark and Tetanus Toxoid From GSK Biologicals' Kft [GD], Compared to the Currently Licensed GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine (Infanrix Hexa TM) When Administered to Healthy Infants at 2, 3 and 4 Months of Age.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00376779

Enrollment

450

Registered

2006-09-15

Start date

2006-10-31

Completion date

2007-05-31

Last updated

2016-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acellular Pertussis, Diphtheria, Haemophilus Influenzae Type b, Hepatitis B, Poliomyelitis, Tetanus

Keywords

Haemophilus influenzae type b, Double-blind, Finland, randomized, phase 2, GSK Biologicals, DTPa-HBV-IPV/Hib

Brief summary

The purpose of this study is to show that the immunogenicity of newly formulated DTPa-HBV-IPV/Hib vaccine is as good as the immunogenicity of the currently licensed formulation of the vaccine. The vaccine will be administered as a primary vaccination course to healthy infants at 2, 3 and 4 months of age and its safety and reactogenicity will also be assessed.

Interventions

BIOLOGICALInfanrix hexa Vaccine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

8 Weeks to 12 Weeks

Healthy volunteers

Yes

Inclusion criteria

* A healthy male or female between, and including, 8 and 12 weeks of age at the time of the first vaccination. * Written informed consent obtained from the parents/guardians of the subject. * Born after a normal gestation period of 36 to 42 weeks.

Exclusion criteria

* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs from birth until first primary vaccination dose. * Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. * Administration/planned administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the administration of the first dose and ending 30 days after the last dose, with the exception of the human rotavirus (HRV) vaccine. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device). * Evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B and/or Haemophilus influenza type b (Hib) vaccination or disease. * Hepatitis B virus (HBV) vaccination at birth. * History of seizures or progressive neurological disease.

Design outcomes

Primary

Measure	Time frame
Antibody concentration/response to all vaccine antigens after vaccination	—

Secondary

Measure	Time frame
Solicited (D0-3); unsolicited events (D0-30); serious adverse events (SAEs) (full study)	—

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026